title: Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.
abstract: A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC) was conducted. Between January 1996 and January 1998, 44 previously untreated patients with stage IIIB or IV NSCLC were enrolled. CDDP at a dose of 60 mg x m(-2) was given first and followed by CPT-11 at a dose of 50 mg x m(-2). Both drugs were given by 1-hour infusion on days 1 and 8, and repeated every 4 weeks up to 4 cycles. 42 patients were evaluated for response and 44 for survival and toxicity. 20 patients (48%: 95% confidence interval 32-63%) achieved an objective response. The median duration of responses was 8 months, and the median survival time and the 1-year survival rate were 12.5 months and 56.8%, respectively. Major toxicities were neutropenia and diarrhoea. Grade 3 or 4 neutropenia occurred in 70.5% of the patients and one patient died of sepsis. Grade 3 or 4 diarrhoea was experienced in 25.0%, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for advanced NSCLC with manageable toxicities.
authors: Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama, 700-8558, Japan.
authors: H
authors: H
authors: Ueoka
authors: M
authors: M
authors: Tanimoto
authors: K
authors: K
authors: Kiura
authors: M
authors: M
authors: Tabata
authors: N
authors: N
authors: Takigawa
authors: Y
authors: Y
authors: Segawa
authors: I
authors: I
authors: Takata
authors: K
authors: K
authors: Eguchi
authors: N
authors: N
authors: Okimoto
authors: S
authors: S
authors: Harita
authors: H
authors: H
authors: Kamei
authors: T
authors: T
authors: Shibayama
authors: Y
authors: Y
authors: Watanabe
authors: S
authors: S
authors: Hiraki
authors: M
authors: M
authors: Harada
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004357:Drug Synergism; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin